Zacks Research Has Weak Estimate for DNLI FY2024 Earnings

Denali Therapeutics Inc. (NASDAQ:DNLI) – Research analysts at Zacks Research decreased their FY2024 EPS estimates for shares of Denali Therapeutics in a research report issued on Tuesday, January 28th. Zacks Research analyst A. Chakraborty now expects that the company will post earnings per share of ($2.77) for the year, down from their previous estimate of ($2.71). The consensus estimate for Denali Therapeutics’ current full-year earnings is ($2.73) per share. Zacks Research also issued estimates for Denali Therapeutics’ Q4 2024 earnings at ($0.87) EPS, Q1 2025 earnings at ($0.83) EPS, Q2 2025 earnings at ($0.84) EPS, Q3 2025 earnings at ($0.83) EPS, Q4 2025 earnings at ($0.87) EPS, FY2025 earnings at ($3.37) EPS, Q1 2026 earnings at ($0.86) EPS, Q2 2026 earnings at ($0.89) EPS, Q3 2026 earnings at ($0.85) EPS, Q4 2026 earnings at ($0.90) EPS and FY2026 earnings at ($3.51) EPS.

Other research analysts have also recently issued research reports about the company. HC Wainwright reduced their target price on Denali Therapeutics from $90.00 to $87.00 and set a “buy” rating on the stock in a research note on Tuesday, January 7th. Jefferies Financial Group increased their price objective on Denali Therapeutics from $40.00 to $45.00 and gave the company a “buy” rating in a research report on Friday, November 1st. Stifel Nicolaus upgraded Denali Therapeutics from a “hold” rating to a “buy” rating and set a $37.00 target price for the company in a research report on Monday, December 16th. The Goldman Sachs Group decreased their price target on shares of Denali Therapeutics from $45.00 to $40.00 and set a “buy” rating on the stock in a research note on Tuesday, January 28th. Finally, Baird R W raised shares of Denali Therapeutics to a “strong-buy” rating in a research note on Tuesday, January 7th. Two research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Denali Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $38.00.

Denali Therapeutics Trading Down 1.2 %

NASDAQ DNLI opened at $23.30 on Friday. Denali Therapeutics has a 12 month low of $14.56 and a 12 month high of $33.33. The firm has a market capitalization of $3.35 billion, a P/E ratio of -8.44 and a beta of 1.39. The business has a fifty day simple moving average of $22.42 and a 200 day simple moving average of $24.83.

Denali Therapeutics (NASDAQ:DNLI) last posted its earnings results on Wednesday, November 6th. The company reported ($0.63) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.03). During the same quarter in the prior year, the company posted ($0.72) earnings per share.

Hedge Funds Weigh In On Denali Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in DNLI. CWM LLC grew its stake in shares of Denali Therapeutics by 43.6% in the third quarter. CWM LLC now owns 2,153 shares of the company’s stock worth $63,000 after acquiring an additional 654 shares during the last quarter. Quest Partners LLC bought a new position in Denali Therapeutics in the 3rd quarter worth about $73,000. Assetmark Inc. grew its position in Denali Therapeutics by 18.0% during the 3rd quarter. Assetmark Inc. now owns 3,808 shares of the company’s stock valued at $111,000 after purchasing an additional 580 shares during the last quarter. KBC Group NV increased its stake in Denali Therapeutics by 75.8% during the 4th quarter. KBC Group NV now owns 6,334 shares of the company’s stock valued at $129,000 after purchasing an additional 2,731 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. raised its holdings in Denali Therapeutics by 21.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,178 shares of the company’s stock worth $152,000 after buying an additional 920 shares during the last quarter. Hedge funds and other institutional investors own 92.92% of the company’s stock.

Insider Transactions at Denali Therapeutics

In other news, CEO Ryan J. Watts sold 29,266 shares of Denali Therapeutics stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $20.22, for a total transaction of $591,758.52. Following the sale, the chief executive officer now owns 260,721 shares of the company’s stock, valued at approximately $5,271,778.62. The trade was a 10.09 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Steve E. Krognes sold 3,339 shares of the business’s stock in a transaction dated Tuesday, January 7th. The shares were sold at an average price of $20.81, for a total transaction of $69,484.59. Following the transaction, the director now owns 25,757 shares in the company, valued at $536,003.17. This represents a 11.48 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 64,518 shares of company stock worth $1,469,382. Company insiders own 7.90% of the company’s stock.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.